TWI916398B - 含有烷基-氧雜環烷基部分之胺磺醯基脲衍生物及其用途 - Google Patents

含有烷基-氧雜環烷基部分之胺磺醯基脲衍生物及其用途

Info

Publication number
TWI916398B
TWI916398B TW110132880A TW110132880A TWI916398B TW I916398 B TWI916398 B TW I916398B TW 110132880 A TW110132880 A TW 110132880A TW 110132880 A TW110132880 A TW 110132880A TW I916398 B TWI916398 B TW I916398B
Authority
TW
Taiwan
Prior art keywords
disease
compound
pharmaceutically acceptable
compounds
cancer
Prior art date
Application number
TW110132880A
Other languages
English (en)
Chinese (zh)
Other versions
TW202229265A (zh
Inventor
馬克 巴克
大衛 哈瑞森
珍 史坎倫
Original Assignee
英商諾得瑟拉公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商諾得瑟拉公司 filed Critical 英商諾得瑟拉公司
Publication of TW202229265A publication Critical patent/TW202229265A/zh
Application granted granted Critical
Publication of TWI916398B publication Critical patent/TWI916398B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110132880A 2020-09-04 2021-09-03 含有烷基-氧雜環烷基部分之胺磺醯基脲衍生物及其用途 TWI916398B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063074521P 2020-09-04 2020-09-04
US63/074,521 2020-09-04

Publications (2)

Publication Number Publication Date
TW202229265A TW202229265A (zh) 2022-08-01
TWI916398B true TWI916398B (zh) 2026-03-01

Family

ID=77951864

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110132880A TWI916398B (zh) 2020-09-04 2021-09-03 含有烷基-氧雜環烷基部分之胺磺醯基脲衍生物及其用途

Country Status (13)

Country Link
US (1) US20240043410A1 (enExample)
EP (1) EP4208459A1 (enExample)
JP (1) JP7865948B2 (enExample)
KR (1) KR20230061505A (enExample)
CN (1) CN116783184A (enExample)
AR (1) AR123435A1 (enExample)
AU (1) AU2021336518B2 (enExample)
BR (1) BR112023003792A2 (enExample)
CA (1) CA3191410A1 (enExample)
IL (1) IL301055A (enExample)
MX (1) MX2023002686A (enExample)
TW (1) TWI916398B (enExample)
WO (1) WO2022051582A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
HUE067378T2 (hu) 2019-06-12 2024-10-28 Nodthera Ltd Szulfonilurea származékok és alkalmazásaik
JP7661248B2 (ja) 2019-06-12 2025-04-14 ノッドセラ リミテッド スルホニル尿素誘導体及びその使用
KR20260115622A (ko) * 2023-11-17 2026-07-24 노드테라 리미티드 우레아 유도체의 제조 방법
CN122555701A (zh) 2023-11-17 2026-08-11 诺瑟拉有限公司 脲衍生物的形式和相关用途
TW202545527A (zh) * 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019121691A1 (en) 2017-12-18 2019-06-27 NodThera Limited Sulphonyl urea derivatives as nlrp3 inflammasome modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
DK1270565T3 (da) 1997-01-29 2004-10-04 Pfizer 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
SG11202101480XA (en) 2018-08-15 2021-03-30 Inflazome Ltd Novel sulfonamideurea compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019121691A1 (en) 2017-12-18 2019-06-27 NodThera Limited Sulphonyl urea derivatives as nlrp3 inflammasome modulators

Also Published As

Publication number Publication date
IL301055A (en) 2023-05-01
CA3191410A1 (en) 2022-03-10
BR112023003792A2 (pt) 2023-03-28
AU2021336518A1 (en) 2023-03-23
EP4208459A1 (en) 2023-07-12
AU2021336518B2 (en) 2026-05-21
MX2023002686A (es) 2023-04-03
AR123435A1 (es) 2022-11-30
JP2023540733A (ja) 2023-09-26
US20240043410A1 (en) 2024-02-08
KR20230061505A (ko) 2023-05-08
JP7865948B2 (ja) 2026-05-26
WO2022051582A1 (en) 2022-03-10
TW202229265A (zh) 2022-08-01
CN116783184A (zh) 2023-09-19

Similar Documents

Publication Publication Date Title
JP7339959B2 (ja) Nlrp3インフラマソーム調節剤としてのスルホニル尿素誘導体
US12227488B2 (en) Small molecule degraders of Helios and methods of use
TWI810198B (zh) Nlrp3發炎體之選擇性抑制劑
TW202229265A (zh) 含有烷基-氧雜環烷基部分之胺磺醯基脲衍生物及其用途
JP2020533288A (ja) Enpp1阻害剤及びがんの治療のためのそれらの使用
JP7661248B2 (ja) スルホニル尿素誘導体及びその使用
WO2023221975A1 (zh) 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
JP7682813B2 (ja) スルホニル尿素誘導体及びその使用
JP2022535955A (ja) スルホンアミド誘導体及びその使用
KR20240145992A (ko) 비사이클릭 프탈라진-1(2h)-온 유도체 및 관련 용도
JP2022518526A (ja) カルバメート誘導体およびその使用
WO2024027795A1 (zh) 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
RU2858266C2 (ru) Производные сульфамоилмочевины, содержащие алкилоксациклоалкильную группу, и их применения